The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Oral and Maxillofacial Surgery Clinics of North America

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.coms.2015.06.003PMID 26362367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic Investigation of Bisphosphonate-Related Osteonecrosis of Jaw (BRONJ) via Whole Exome Sequencing and Bioinformatics

  2015cited by this paper
• Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

  2015cited by this paper
• Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

  2015cited by this paper
• Diabetes as a Risk Factor for Medication-Related Osteonecrosis of the Jaw

  2015cited by this paper
• Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results

  2014cited by this paper
• Medication-Related Osteonecrosis of the Jaw—2014 Update

  2014cited by this paper
• Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

  2014cited by this paper
• Gender related difference in the risk of bisphosphonate associated atypical femoral fracture and osteonecrosis of the jaw

  2014cited by this paper
• Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials

  2014cited by this paper
• Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

  2014cited by this paper
• American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

  2014cited by this paper
• Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.

  2014cited by this paper
• A Large Case‐Control Study Reveals a Positive Association Between Bisphosphonate Use and Delayed Dental Healing and Osteonecrosis of the Jaw

  2014cited by this paper
• Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

  2014cited by this paper
• The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

  2013cited by this paper
• Systematic Review on the Incidence of Bisphosphonate Related Osteonecrosis of the Jaw in Children Diagnosed with Osteogenesis Imperfecta

  2013cited by this paper
• Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol.

  2013cited by this paper
• Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors

  2013cited by this paper
• Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan.

  2013cited by this paper
• Oral health risk factors for bisphosphonate-associated jaw osteonecrosis.

  2013cited by this paper
• Association between CYP2C8 (rs1934951) Polymorphism and Bisphosphonate-Related Osteonecrosis of the Jaws in Patients on Bisphosphonate Therapy: A Meta-Analysis

  2012cited by this paper
• Tooth extraction in patients on zoledronic acid therapy.

  2012cited by this paper
• Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

  2012cited by this paper
• Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study.

  2012cited by this paper
• An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence

  2012cited by this paper
• New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.

  2012cited by this paper
• Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3.

  2012cited by this paper
• An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.

  2012cited by this paper
• Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

  2012cited by this paper
• Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

  2011cited by this paper
• Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.

  2011cited by this paper
• Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.

  2011cited by this paper
• Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

  2010cited by this paper
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

  2010cited by this paper
• Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.

  2010cited by this paper
• The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.

  2010cited by this paper
• Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

  2009cited by this paper
• Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.

  2009cited by this paper
• Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

  2009cited by this paper
• Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.

  2009cited by this paper
• Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.

  2008cited by this paper
• Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

  2003cited by this paper

• Case Report: Surgical treatment of stage 3 medication-related osteonecrosis of the maxilla using the “FTT Split” surgical protocol: a report of 14 cases

  2026cites this paper
• Advancements in Bone Replacement Techniques–Potential Uses After Maxillary and Mandibular Resections Due to Medication-Related Osteonecrosis of the Jaw (MRONJ)

  2025cites this paper
• Medication-Related Osteonecrosis of the Jaw in the Pediatric Population: A Systematic Review of Current Literature.

  2025cites this paper
• Medication-related osteonecrosis of the jaw in an older patient with multiple myeloma.

  2025cites this paper
• Monoclonal Antibodies and Osteonecrosis of the Jaw: A Systematic Review of Risk, Incidence, and Clinical Management in Dentistry

  2025cites this paper
• Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw.

  2025cites this paper
• A GelMA/polydopamine hydrogel with PTH and osteogenically stimulated alveolar mucosa-derived stem cells promotes bone regeneration in MRONJ-affected wounds

  2025influential citation
• Examination of certain single-nucleotide polymorphisms of interleukins 1A and 1B in medication-related osteonecrosis of the jaw - An ambirectional cohort study.

  2024cites this paper
• Laser technology in periodontics

  2024cites this paper
• Bone complications of cancer treatment.

  2024cites this paper
• Management of Medication-Related Osteonecrosis of the Jaw: An Overview of National and International Guidelines.

  2024cites this paper
• Dental implants in oral rehabilitation after denosumab and bisphosphonate-related osteonecrosis of the jaw in a young patient: an unusual case

  2024cites this paper
• Treatment of Medication-Related Osteonecrosis of the Jaws without Segmental Resections: A Case Series

  2024influential citation
• MRONJ Treatment Strategies: A Systematic Review and Two Case Reports

  2023cites this paper
• A Case Report of Ibandronic Acid Induced Non-Exposed BRONJ Involving the Maxillary Sinus

  2023cites this paper
• A Comparison of 18F-FDG PET/CT and 68Ga-PSMA PET/CT in Detecting Osteonecrosis of the Jaw in a Patient With Prostate Cancer.

  2023cites this paper
• Is maxillary sinusitis and radiographic maxillary sinus opacification associated with an altered microbiology of MRONJ?

  2023cites this paper
• Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention

  2023cites this paper
• Awareness, perceptions and attitudes toward medication-related osteonecrosis of the jaw among physicians who treat osteoporosis

  2023influential citation
• Einfluss von Zoledronat und Denosumab auf humane Zellen der osteoblastären Linie aus dem Kieferknochen anhand osteogener Marker

  2023cites this paper
• Evaluation of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Terms of Staging and Treatment Strategies by Dental Students at Different Educational Levels

  2023cites this paper
• Awareness and Attitude Among Physicians' About Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ): A Cross-sectional study.

  2022cites this paper
• [Bisphosphonate-related osteonecrosis of the jaws].

  2022cites this paper
• Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan

  2022cites this paper
• Association Between Malignant Diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis

  2022cites this paper
• A systematic review assessing occurrence of medication-related osteonecrosis of the jaw following dental procedures

  2022cites this paper
• Interventions for managing medication-related osteonecrosis of the jaw.

  2022cites this paper
• Can topical phenytoin combined with tetracycline enhance the healing process in medication-related osteonecrosis of jaw? A comparative study

  2022cites this paper
• Knowledge of dental professionals and Dental students on bisphosphonates and bisphosphonate-associated osteonecrosis of the jaws

  2022cites this paper
• Roles of osteoclasts in alveolar bone remodeling

  2022cites this paper
• Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center

  2022influential citation
• Actinomycosis and osteonecrosis of the jaw: every why hides a why.

  2022cites this paper
• Oral Complications in Cancer Patients–Medication-Related Osteonecrosis of the Jaw (MRONJ)

  2022cites this paper
• Assessment of Awareness and Knowledge of Medication Related Osteonecrosis of Jaw among Dental Students at a Tertiary Hospital in Eastern Nepal

  2021cites this paper
• Underprescription of medications in older adults: causes, consequences and solutions—a narrative review

  2021cites this paper
• Human amniotic membrane: an improvement in the treatment of Medication-related osteonecrosis of the jaw (MRONJ)? A case–control study

  2021cites this paper
• Human amniotic membrane in the treatment of MRONJ

  2021cites this paper
• Bisphosphonates in Dentistry – State of the Art

  2021cites this paper
• Alendronate-induced Perturbation of the Bone Proteome and Microenvironmental Pathophysiology

  2021influential citation
• Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: systematic review.

  2021cites this paper
• Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology

  2021cites this paper
• Disorders of the Endocrine System and of Metabolism

  2021cites this paper
• A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities

  2021cites this paper
• Medication-Related Osteonecrosis of the Jaws

  2021cites this paper
• Conservative Management of Severe Medication-Related Osteonecrosis of the Jaw With Pathological Fracture

  2021cites this paper
• Medication-Related Osteonecrosis of the Jaw—A Continuing Issue

  2021cites this paper
• Medication-Related Osteonecrosis of the Jaw: A Critical Narrative Review

  2021cites this paper
• Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw

  2021cites this paper
• Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab

  2021cites this paper
• The incidence of medication-related osteonecrosis of the jaw following tooth extraction in patients prescribed oral bisphosphonates.

  2021cites this paper
• Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan.

  2021cites this paper
• Medication-Related Osteonecrosis of the Jaw, a Hidden Enemy. An Integrative Review

  2021cites this paper
• Bone‐Specific Drugs and Osteonecrosis of Sites Other Than the Jaw: A Nationwide Cohort Study

  2020cites this paper
• Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts

  2020cites this paper
• Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report.

  2020cites this paper
• Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw

  2020cites this paper
• Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study

  2020cites this paper
• Role of osteoclasts in oral homeostasis and jawbone diseases.

  2020cites this paper
• Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study

  2020cites this paper
• MRONJ: comparison between two surgical approaches

  2020cites this paper
• Medication‐related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications

  2020cites this paper
• Osteonecrosis of the jaw in a patient under treatment of osteoporosis with oral bisphosphonate

  2020cites this paper
• Bisphosphonate-related osteonecrosis of the jaw (BRONJ) in cancer patients

  2020cites this paper
• Implant Related MRONJ – A Case of Partial Mandibulectomy in the Medically Compromised Elderly Patient

  2020influential citation
• Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis.

  2020cites this paper
• Predictive risk factors of medication-related osteonecrosis of the jaw

  2019cites this paper
• Radiopacities

  2019cites this paper
• Medullary Thyroid Cancer

  2019cites this paper
• World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2019): Non-Sponsored Symposia Abstracts

  2019cites this paper
• Updated clinical guidelines on the oral management of oncology patients

  2019cites this paper
• Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale

  2019cites this paper
• Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review.

  2019cites this paper
• Skeletal Site-Specific Response of Jawbones and Long Bones to Surgical Interventions in Rats Treated with Zoledronic Acid

  2019cites this paper
• Uncommon presentation of medication-related osteonecrosis of the mandible in a patient with metastatic prostate cancer

  2019cites this paper
• Osteonecrosis

  2019cites this paper
• Association between periodontitis and medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.

  2019cites this paper
• Medication-Related Osteonecrosis of the Jaws.

  2019cites this paper
• Bilateral Bone Ridge Splitting in Maxilla with Immediate Implant Placement in a Patient with Osteoporosis: A Clinical Report with 2-Year Follow-up

  2019cites this paper
• Medication-Related Osteonecrosis of the Jaw: An Overview

  2019cites this paper
• Medication related osteonecrosis of the jaws: Prospective cohort study analysing the aetiology, microbiology, and response to surgical debridement with adjunctive leucocyte and platelet rich fibrin (L-PRF)

  2018cites this paper
• Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws.

  2018cites this paper
• Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database

  2018cites this paper
• Efficacy of bovine lactoferrin in the post-surgical treatment of patients suffering from bisphosphonate-related osteonecrosis of the jaws: an open-label study

  2018cites this paper
• Radiographic predictors of bone exposure in stage 0 MRONJ patients

  2018cites this paper
• Medication-related osteonecrosis of the jaws ( MRONJ ) review : what Irish dentists need to know , from international guidelines to current controversies

  2018cites this paper
• Patienten mit speziellem Therapiebedarf

  2017cites this paper
• Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users

  2017cites this paper
• Diabetes, bone and glucose-lowering agents: clinical outcomes

  2017cites this paper
• Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties.

  2017cites this paper
• Otorhinolaryngological Toxicities of New Drugs in Oncology

  2017cites this paper
• Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - A retrospective cohort study.

  2017cites this paper
• Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review.

  2017cites this paper
• Interventions for managing medication-related osteonecrosis of the jaw.

  2017cites this paper
• Co-presence of bisphosphonate-related osteonecrosis of the jaw and oral squamous cell carcinoma in a patient with postmenopausal osteoporosis: a role for chronic traumatism?

  2017cites this paper
• Jaw Pain in a Pemphigus Patient on Prednisolone, Mycophenolate Mofetil and Denosumab.

  2017cites this paper
• Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series.

  2016cites this paper
• Prevenzione e management odontoiatrico dei pazienti oncologici a rischio di osteonecrosi delle ossa mascellari da farmaci

  2016cites this paper
• Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences.

  2016cites this paper
• Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience

  2016cites this paper
• Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.

  2016cites this paper